Early cancer drug study focuses on how genetics affect medication processing
NCT ID NCT02680795
Summary
This early-phase study examined how the cancer drug belinostat is processed by the body in patients with advanced solid tumors or blood cancers that have returned or stopped responding to treatment. Researchers specifically looked at how different genetic variations affect drug processing and safety. The study involved 17 patients who received the drug for 5 days during a 21-day cycle while their blood and urine were tested.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
John Wayne Cancer Institute @ Providence Saint John's Health Center
Santa Monica, California, 90404, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States
Conditions
Explore the condition pages connected to this study.